Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

Siliciano, Janet D, Kajdas, Joleen, Finzi, Diana, Quinn, Thomas C, Chadwick, Karen, Margolick, Joseph B, Kovacs, Colin, Gange, Stephen J +1 more·2003·Nature Medicine
DOI 10.1038/nm880

Cited by (1,001)

Items 201–300 of 1,001

  1. Broadly neutralizing antibody–derived CAR T cells reduce viral reservoir in individuals infected with HIV-1
    Bingfeng Liu, Wanying Zhang, Baijin Xia, Shuliang Jing, Yingying Du, Fan Zou, Rong Li, Lijuan Lu, Shaozhen Chen, Yonghong Li et al. · 2021 · Journal of Clinical Investigation
  2. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog
    Doyon, Geneviève, Zerbato, Jennifer, Mellors, John W., Sluis-Cremer, Nicolas · 2013 · AIDS
  3. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV ‐1 reservoirs: results from a multicentre randomized clinical study
    Routy Jp, Cecile L. Tremblay, Jonathan Benjamin Angel, Benoît Trottier, Danielle Rouleau, Jean-Guy Baril, M. J. Harris, Sylvie Trottier, Joel Singer, Nicolas Chomont et al. · 2012 · HIV Medicine
  4. Mechanisms of CD8 + T cell‐mediated suppression of HIV/SIV replication
    Julia Bergild McBrien, Nitasha Kumar, Guido Silvestri · 2018 · European Journal of Immunology
  5. CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells
    Mohamed Abdel‐Mohsen, Leticia Kuri-Cervantes, Judith Grau-Expósito, Adam M. Spivak, Racheal A. Nell, Costin Tomescu, Surya Kumari Vadrevu, Leila B. Giron, Carla Serra‐Peinado, Meritxell Genescà et al. · 2018 · Science Translational Medicine
  6. Current status of gene therapy strategies to treat HIV/AIDS
    David S. Strayer, Ramesh Akkina, Bruce Alan Bunnell, Boro Dropulić, Vicente Planelles, Roger J. Pomerantz, John J. Rossi, John A. Zaia · 2005 · Molecular Therapy
  7. Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
    Alexander O. Pasternak, Suzanne Jurriaans, Margreet E. Bakker, Jan M. Prins, Ben Berkhout, Vladimir V. Lukashov · 2009 · PLoS ONE
  8. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption
    D. Brenda Salantes, Yu Zheng, Felicity Mampe, Tuhina Srivastava, Subul A. Beg, Jun Lai, Jonathan Z. Li, Randall L. Tressler, Richard A. Koup, James A. Hoxie et al. · 2018 · Journal of Clinical Investigation
  9. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication
    Kenji Maeda, Debananda Das, Takuya Kobayakawa, Hirokazu Tamamura, Hiroaki Takeuchi · 2019 · Current Topics in Medicinal Chemistry
  10. Single-cell transcriptional landscapes reveal HIV-1–driven aberrant host gene transcription as a potential therapeutic target
    Runxia Liu, Yang-Hui Jimmy Yeh, Ales Varabyou, Jack A. Collora, Scott A. Sherrill-Mix, C. Conover Talbot, Sameet S. Mehta, Kristen Albrecht, Haiping Hao, Hao Zhang et al. · 2020 · Science Translational Medicine
  11. In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA
    Mark E. Sharkey, Karine Triques, Daniel R. Kuritzkes, Mario Stevenson · 2005 · Journal of Virology
  12. Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants
    John Burnett, Kwang‐il Lim, Arash Calafi, John J. Rossi, David V. Schaffer, Adam P. Arkin · 2010 · Journal of Virology
  13. Progress in HIV vaccine development
    Denise C. Hsu, Robert J. O’Connell · 2017 · Human Vaccines & Immunotherapeutics
  14. The Current Status of Latency Reversing Agents for HIV-1 Remission
    Anthony Rodari, Gilles Darcis, Carine M. Van Lint · 2021 · Annual Review of Virology
  15. Viral and Latent Reservoir Persistence in HIV-1 Infected Patients on Therapy
    Hwijin Kim, Alan S. Perelson · 2005 · PLoS Computational Biology
  16. Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads
    Deborah Persaud, George Kelly Siberry, Aima A. Ahonkhai, Joleen Kajdas, Daphne Monie, Nancy Hutton, Douglas C. Watson, Thomas C. Quinn, Stuart C. Ray, Robert F. Siliciano · 2003 · Journal of Virology
  17. Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency
    Todd Bradley, Guido Ferrari, Barton F. Haynes, David M. Margolis, Edward P. Browne · 2018 · Cell Reports
  18. An AP-1 Binding Site in the Enhancer/Core Element of the HIV-1 Promoter Controls the Ability of HIV-1 To Establish Latent Infection
    Alexandra Emilie Duverger, Frank Wolschendorf, Mingce Zhang, Fredric Wagner, Brandon Hatcher, Jennifer Jones, Randy Quentin Cron, Renée Marije van der Sluis, Rienk E. Jeeninga, Ben Berkhout et al. · 2012 · Journal of Virology
  19. HIV-1 Eradication: Early Trials (and Tribulations)
    Adam M. Spivak, Vicente Planelles · 2015 · Trends in Molecular Medicine
  20. Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
    Alison L. Hill, Daniel I. S. Rosenbloom, Edward Goldstein, Emily Hanhauser, Daniel R. Kuritzkes, Robert F. Siliciano, Timothy J. Henrich · 2016 · PLoS Pathogens
  21. Are T cells the only HIV-1 reservoir?
    Abraham Joseph Kandathil, Sho Sugawara, Ashwin Balagopal · 2016 · Retrovirology
  22. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells
    Derek D. Sloan, Chia‐Ying K. Lam, Alivelu Irrinki, Liqin Liu, Angela Tsai, Craig S. Pace, Jasmine Kaur, Jeffrey P. Murry, Mini Balakrishnan, Paul A. Moore et al. · 2015 · PLoS Pathogens
  23. Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA
    Feiyu F. Hong, Evgenia Aga, Anthony Richard Cillo, A. Lowndes Yates, Guillaume J. Besson, Elizabeth Fyne, Dianna L. Koontz, Cheryl Jennings, Lu Zheng, John W. Mellors · 2016 · Journal of Clinical Microbiology
  24. A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4 + T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients
    Judith Grau-Expósito, Carla Serra‐Peinado, Lucia Miguel-Escuder, Jordi Navarro, Adrián Curran, Joaquín Burgos, Imma Ocaña, Esteban Ribera, Ariadna Torrella, Bibiana Planas et al. · 2017 · mBio
  25. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection
    Lorna Leal, Alberto Crespo Guardo, Sara Morón‐López, María Salgado, Beatriz Mothe, Carlo Heirman, Pieter Pannus, Guido Vanham, Henk‐Jan van den Ham, Rob A. Gruters et al. · 2018 · AIDS
  26. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4 + T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy
    Bingfeng Liu, Fan Zou, Lijuan Lu, Cancan Chen, Dalian He, Xu Zhang, Xiaoping Tang, Chao Liu, Linghua Li, Hui Zhang · 2016 · Journal of Virology
  27. Control of HIV Latency by Epigenetic and Non-Epigenetic Mechanisms
    Jonathan Karn, Uri R. Mbonye · 2011 · Current HIV Research
  28. Signaling through Toll-Like Receptors Triggers HIV-1 Replication in Latently Infected Mast Cells
    Jay Bruce Sundstrom, Dawn M. Little, Francois J. Villinger, Jane E. Ellis, Aftab Ahmed Ansari · 2004 · The Journal of Immunology
  29. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth
    Maja Kiselinova, Ward De Spiegelaere, Maria José Buzón, Eva Malatinková, Mathias D. Lichterfeld, Linos Vandekerckhove · 2016 · PLoS Pathogens
  30. Engaging innate immunity in HIV-1 cure strategies
    Nathan L. Board, Milica Moskovljevic, Fengting Wu, Robert F. Siliciano, Janet D'Angelo Siliciano · 2021 · Nature reviews. Immunology
  31. Role of β-Catenin and TCF/LEF Family Members in Transcriptional Activity of HIV in Astrocytes
    Srinivas D. Narasipura, Lisa J. Henderson, Sidney W. Fu, Liang Chen, Fatah Kashanchi, Lena Al‐Harthi · 2011 · Journal of Virology
  32. Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensis
    Ruirui Wang, Qiong Gu, Yunhua Wang, Xuemei Zhang, Liu‐Meng Yang, Jun Zhou, Ji‐Jun Chen, Yong‐Tang Zheng · 2008 · Journal of Ethnopharmacology
  33. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy
    Hong Sun, Dhohyung Kim, Xiaodong Li, Maja Kiselinova, Zhengyu Ouyang, Linos Vandekerckhove, Hong Shang, Eric S. Rosenberg, Xu G. Yu, Mathias D. Lichterfeld · 2015 · Journal of Virology
  34. Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected
    Carolina Gutiérrez, Laura Díaz, Alejandro Vallejo, Beatriz Hernández‐Novoa, María Abad-Fernández, Nadia Madrid, Viktor Dahl, Rafael Rubio, Ana Maria Moreno, Fernando Dronda et al. · 2011 · PLoS ONE
  35. Measuring the Frequency of Latent HIV-1 in Resting CD4+ T Cells Using a Limiting Dilution Coculture Assay
    Gregory M. Laird, Daniel I. S. Rosenbloom, Jun Lai, Robert F. Siliciano, Janet D'Angelo Siliciano · 2015 · Methods in molecular biology
  36. The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections
    Alexandra M. Bender, Francesco Roberto Simonetti, Mithra R. Kumar, Emily J. Fray, Katherine M. Bruner, Andrew E. Timmons, Katherine Yuxi Tai, Katharine M. Jenike, Annukka A.R. Antar, Po-Ting Liu et al. · 2019 · Cell Host & Microbe
  37. A Doubly Fluorescent HIV-1 Reporter Shows that the Majority of Integrated HIV-1 Is Latent Shortly after Infection
    Matthew S. Dahabieh, Marcel Ooms, Viviana R. Simon, Ivan Sadowski · 2013 · Journal of Virology
  38. Influence of Age at Virologic Control on Peripheral Blood Human Immunodeficiency Virus Reservoir Size and Serostatus in Perinatally Infected Adolescents
    Deborah Persaud, Kunjal Patel, Brad Karalius, Kaitlin Rainwater‐Lovett, Carrie Ziemniak, Angela Ellis, Ya Hui Chen, Douglas D. Richman, George Kelly Siberry, Russell B. Van Dyke et al. · 2014 · Archives of Pediatrics and Adolescent Medicine
  39. A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir
    Claire Levy, Sean M. Hughes, Pavitra Roychoudhury, Daniel B. Reeves, Chelsea Amstuz, Haiying Zhu, Meei-Li W. Huang, Yulun Wei, Marta E. Bull, Noah A.J. Cassidy et al. · 2021 · Cell Reports Medicine
  40. The multifaceted nature of HIV latency
    Caroline Dufour, Pierre Gantner, Rémi Fromentin, Nicolas Chomont · 2020 · Journal of Clinical Investigation
  41. Resting Regulatory CD4 T Cells: A Site of HIV Persistence in Patients on Long-Term Effective Antiretroviral Therapy
    Tú-Anh Tran, Marie-Ghislaine de Goër de Herve, Houria Hendel, Bamory Dembelé, Emilie le Névot, Karim Abbed, Coralie Pallier, Cécile Goujard, Jacques Gasnault, Jean‐François Delfraissy et al. · 2008 · PLoS ONE
  42. Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1
    Claudia Arenaccio, Simona Anticoli, Francesco Manfredi, Chiara Chiozzini, Eleonora Olivetta, Maurizio Federico · 2015 · Retrovirology
  43. Different human resting memory CD4 + T cell subsets show similar low inducibility of latent HIV-1 proviruses
    Kyungyoon J. Kwon, Andrew E. Timmons, Srona Sengupta, Francesco Roberto Simonetti, Hao Zhang, Rebecca Hoh, Steven G. Deeks, Janet D'Angelo Siliciano, Robert F. Siliciano · 2020 · Science Translational Medicine
  44. Effector mechanisms in HIV-1 infected elite controllers: Highly active immune responses?
    Joel N. Blankson · 2009 · Antiviral Research
  45. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy
    Radjin Steingrover, Katalyn Pogány, Evian Fernandez Garcia, Suzanne Jurriaans, Kees Brinkman, Hanneke Schuitemaker, Frank F. Miedema, Joep M. A. Lange, Jan M. Prins · 2008 · AIDS
  46. Immunological approaches to HIV cure
    Adam R. Ward, Talia M. Mota, Richard Brad Jones · 2020 · Seminars in Immunology
  47. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells
    Alberto Bosque, Vicente Planelles · 2010 · Methods
  48. Developing strategies for HIV-1 eradication
    Christine M. Durand, Joel N. Blankson, Robert F. Siliciano · 2012 · Trends in Immunology
  49. In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure
    Janet D'Angelo Siliciano, Robert F. Siliciano · 2021 · Annual Review of Pathology Mechanisms of Disease
  50. Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy
    Jennifer A. White, Francesco Roberto Simonetti, Subul A. Beg, Natalie F. McMyn, Weiwei Dai, Niklas Bachmann, Jun Lai, William C. Ford, Christina Bunch, Joyce L Jones et al. · 2022 · Proceedings of the National Academy of Sciences
  51. Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART
    Pierre Delobel, Karine Sauné, Michelle Cazabat, Fatima-Ezzahra L'Faqihi, Christian Aquilina, Martine Obadia, Christophe Pasquier, Bruno Marchou, Patrice Massip, Jacques Izopet · 2005 · AIDS
  52. Mechanisms of HIV Latency: an Emerging Picture of Complexity
    David M. Margolis · 2010 · Current HIV/AIDS Reports
  53. Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV
    Geetha Mylvaganam, Lynette S. Chea, Gregory K. Tharp, Sakeenah L. Hicks, Vijayakumar Velu, Smita Swaminathan Iyer, Claire Deléage, Jacob D. Estes, Steven E. Bosinger, Gordon James Freeman et al. · 2018 · JCI Insight
  54. Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals
    Line K. Vibholm, Christina Valbirk Konrad, Mariane Høgsbjerg Schleimann, Giacomo Schmidt Frattari, Anni Assing Winckelmann, Vibeke Klastrup, Nanna Møller Jensen, Sanne Skov Jensen, Manuel Schmidt, Burghardt Wittig et al. · 2019 · AIDS
  55. The evolution of HIV: Inferences using phylogenetics
    Eduardo Castro‐Nallar, Marcos Pérez‐Losada, Gregory F. Burton, Keith A. Crandall · 2011 · Molecular Phylogenetics and Evolution
  56. Ultrasensitive Assessment of Residual Low-Level HIV Viremia in HAART-Treated Patients and Risk of Virological Failure
    Franco Maggiolo, Annapaola Callegaro, Giuliana Cologni, Claudia Bernardini, Daniela Velenti, Giampietro Gregis, Giampaolo Quinzan, Laura Soavi, Nathalie Iannotti, Emanuele Nadir Malfatto et al. · 2012 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  57. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
    Lı́dia Ruiz, Roger Paredes, Guadalupe Gómez Melis, Joan Romeu, Peré Domingo, Núria Pérez‐Álvarez, Giuseppe Tambussi, Josep Maria Llibre, Javier Martínez‐Picado, Francesc Vidal et al. · 2006 · AIDS
  58. Dual Role of Novel Ingenol Derivatives from Euphorbia tirucalli in HIV Replication: Inhibition of De Novo Infection and Activation of Viral LTR
    Celina Monteiro Abreu, Sarah L. Price, Erin N. Shirk, Rodrigo Delvecchio da Cunha, Luiz Francisco Pianowski, Janice E. Clements, Amílcar Tanuri, Lúcio Gama · 2014 · PLoS ONE
  59. Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance
    Xiaobin Lu, Qiao Yu, Gwendolyn K. Binder, Zi-Ping Chen, T. Slepushkina, J. Rossi, B. Dropulić · 2004 · Journal of Virology
  60. Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age
    Deborah Persaud, Paul E Palumbo, Carrie Ziemniak, Michael D. Hughes, Carmelita G. Alvero, Katherine Luzuriaga, Ram Yogev, Edmund V. Capparelli, ELLEN GOULD CHADWICK · 2012 · AIDS
  61. New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System
    Victoria Rojas-Celis, Fernando Valiente‐Echeverría, Ricardo Soto‐Rifo, Daniela Toro‐Ascuy · 2019 · Cells
  62. MicroRNAs and exosomes: key players in HIV pathogenesis
    Javid Sadri Nahand, Farah Bokharaei‐Salim, Mohammad Reza Karimzadeh, Mohsen Moghoofei, Sajad Karampoor, HR Mirzaei, Alireza Tabibzadeh, Amir Homayoun Jafari, Amir Ghaderi, Zatollah Asemi et al. · 2019 · HIV Medicine
  63. The therapeutic application of CRISPR/Cas9 technologies for HIV
    Sheena M. Saayman, Stuart Alvaro Ali, Kevin V. Morris, Marc S. Weinberg · 2015 · Expert Opinion on Biological Therapy
  64. Latent HIV-1 Infection of Resting CD4 + T Cells in the Humanized Rag2 −/− γ c −/− Mouse
    Shailesh Kumar Choudhary, Nancie M. Archin, MA Cheema, Noelle Dahl, J. Víctor García, David M. Margolis · 2011 · Journal of Virology
  65. CRISPR-Cas based antiviral strategies against HIV-1
    Gang Wang, Na Zhao, Ben Berkhout, Atze T. Das · 2017 · Virus Research
  66. Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia
    Jennifer A. White, Fengting Wu, Saif Yasin, Milica Moskovljevic, Joseph Varriale, Filippo Dragoni, Angelica Camilo-Contreras, Jiayi Duan, Mei Y. Zheng, Ndeh F. Tadzong et al. · 2023 · Journal of Clinical Investigation
  67. HIV DNA Subspecies Persist in both Activated and Resting Memory CD4 + T Cells during Antiretroviral Therapy
    John Michael Murray, John James Zaunders, Kristin L. McBride, Yin Xu, Michelle Bailey, Kazuo Suzuki, David A. Cooper, Sean Emery, Anthony Dominic Kelleher, Kersten K. Koelsch · 2014 · Journal of Virology
  68. Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna
    Swiss HIV Cohort Study, Sara Gianella, Viktor von Wyl, Marek Fischer, Barbara P. Niederöst, Manuel Battegay, Enos Bernasconi, Matthias L. Cavassini, Andri Rauch, Bernard J. Hirschel et al. · 2010 · Antiviral Therapy
  69. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals
    Yves Lévy, Christine Durier, Anne‐Sophie Lascaux, Vincent Meiffrédy, Hanne Gahéry‐Ségard, Cécile Goujard, Christine Rouzioux, Martine Resch, Jean‐Gérard Guillet, Michel Daniel Kazatchkine et al. · 2006 · AIDS
  70. Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates
    Freeling, Jennifer P., Koehn, Josefin, Shu, Cuiling, Sun, Jianguo, Ho, Rodney J.Y. · 2015 · AIDS Research and Human Retroviruses
  71. Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients
    Adam M. Spivak, Alberto Bosque, Alfred H. Balch, David R. Smyth, Laura J. Martins, Vicente Planelles · 2015 · Antimicrobial Agents and Chemotherapy
  72. An Increasing Proportion of Monotypic HIV-1 DNA Sequences during Antiretroviral Treatment Suggests Proliferation of HIV-Infected Cells
    Thor A. Wagner, Jennifer L. McKernan, Nicole H. Tobin, Ken Tapia, James I. Mullins, Lisa M. Frenkel · 2012 · Journal of Virology
  73. Chromatin Reassembly Factors Are Involved in Transcriptional Interference Promoting HIV Latency
    Edurne Gallastegui, Gonzalo Millán-Zambrano, Jean-Michel Terme, Sebastián Chávez, Albert Jordan · 2011 · Journal of Virology
  74. Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy
    Christian Lorenz Althaus, Rob J. de Boer · 2010 · Molecular Systems Biology
  75. A Stochastic Model of Latently Infected Cell Reactivation and Viral Blip Generation in Treated HIV Patients
    Jessica M. Conway, Daniel Coombs · 2011 · PLoS Computational Biology
  76. Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring
    Mark A. Lifson, Mehmet Ozgün Ozen, Fatih İnci, Shuqi Wang, Hakan Inan, Murat Baday, Timothy J. Henrich, Utkan Demirci · 2016 · Advanced Drug Delivery Reviews
  77. Myeloid and CD4 T Cells Comprise the Latent Reservoir in Antiretroviral Therapy-Suppressed SIVmac251-Infected Macaques
    Celina Monteiro Abreu, Rebecca T. Veenhuis, Claudia R. Avalos, Shelby Graham, Daymond R. Parrilla, Edna A. Ferreira, Suzanne E. Queen, Erin N. Shirk, Brandon T. Bullock, Ming Li et al. · 2019 · mBio
  78. From reactivation of latent HIV‐1 to elimination of the latent reservoir: The presence of multiple barriers to viral eradication
    Liang Shan, Robert F. Siliciano · 2013 · BioEssays
  79. Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency
    Shailesh Kumar Choudhary, David M. Margolis · 2011 · The Annual Review of Pharmacology and Toxicology
  80. Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1
    Janet D'Angelo Siliciano, Robert F. Siliciano · 2014 · Journal of Allergy and Clinical Immunology
  81. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1
    Lynn N. Bertagnolli, Joseph Varriale, Sarah E. Sweet, Jacqueline Brockhurst, Francesco Roberto Simonetti, Jennifer White, Subul A. Beg, Kenneth Lynn, Karam Mounzer, Ian Frank et al. · 2020 · Proceedings of the National Academy of Sciences
  82. The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro
    Shay Matalon, Brent E. Palmer, Marcel F. Nold, Antonio Furlan, Afework Kassu, Gianluca Fossati, Paolo Mascagni, Charles Anthony Dinarello · 2010 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  83. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV
    Nicolas Chomont, Sandrina DaFonseca, Claire Vandergeeten, Petronela Ancuța, Rafick‐Pierre Sékaly · 2010 · Current Opinion in HIV and AIDS
  84. HIV-1 DNA sequence diversity and evolution during acute subtype C infection
    Guinevere Q. Lee, Kavidha Reddy, Kevin B. Einkauf, Kamini Gounder, Joshua M Chevalier, Krista L. Dong, Bruce D. Walker, Xu G. Yu, Thumbi Ndung’u, Mathias D. Lichterfeld · 2019 · Nature Communications
  85. Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy
    Annukka A.R. Antar, Katharine M. Jenike, Sunyoung Jang, Danielle N. Rigau, Daniel B. Reeves, Rebecca Hoh, Melissa Krone, Jeanne C. Keruly, Richard D. Moore, Joshua Tisdell Schiffer et al. · 2020 · Journal of Clinical Investigation
  86. Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment
    Jay Rappaport, David J. Volsky · 2015 · Journal of NeuroVirology
  87. Peptide‐loaded dendritic‐cell vaccination followed by treatment interruption for chronic HIV‐1 infection: A phase 1 trial
    F. Ide, Tetsuya Nakamura, Mariko Tomizawa, Ai Kawana‐Tachikawa, Takashi Odawara, Noriaki Hosoya, Aikichi Iwamoto · 2006 · Journal of Medical Virology
  88. Antiretroviral drugs
    Mira K. Desai, Geetha Iyer, RK Dikshit · 2012 · Indian Journal of Pharmacology
  89. Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs
    Amy E. Baxter, Una O’Doherty, DE Kaufmann · 2018 · Retrovirology
  90. Deep latency: A new insight into a functional HIV cure
    Maher M. Elsheikh, Yuyang Tang, Dajiang Li, Guochun Jiang · 2019 · EBioMedicine
  91. HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency
    Shigeki Hoshino, Mitsuru Konishi, Masako Mori, Mari Shimura, Chiaki Nishitani, Yoshio Kuroki, Yoshio Koyanagi, Shigeyuki Kano, Hiroyuki Itabe, Yukihito Ishizaka · 2010 · Journal of Leukocyte Biology
  92. HIV-1 Latency: An Update of Molecular Mechanisms and Therapeutic Strategies
    Angela Battistini, Marco Sgarbanti · 2014 · Viruses
  93. Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1
    Jennifer M. Zerbato, Deborah K. McMahon, Michelle D Sobolewski, John W. Mellors, Nicolas Sluis‐Cremer · 2019 · Clinical Infectious Diseases
  94. Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines
    Sean Matthew McCauley, Kyusik Kim, Anetta Nowosielska, Ann Dauphin, Leonid Yurkovetskiy, William E. Diehl, Jeremy Luban · 2018 · Nature Communications
  95. Hematopoietic stem/precursor cells as HIV reservoirs
    Lucy A. McNamara, Kathleen L. Collins · 2010 · Current Opinion in HIV and AIDS
  96. Transcription: Insights From the HIV-1 Promoter
    Enrico Ne, Robert-Jan T. S. Palstra, Tokameh Mahmoudi · 2017 · International review of cytology
  97. Newer Gene Editing Technologies toward HIV Gene Therapy
    Manjunath, N., Yi, Guohua, Dang, Ying, Shankar, Premlata · 2013 · Viruses
  98. Are microRNAs Important Players in HIV-1 Infection? An Update
    Muthukumar Balasubramaniam, Jui Pandhare, Chandravanu Dash · 2018 · Viruses
  99. Relationship between intact HIV-1 proviruses in circulating CD4 <sup>+</sup> T cells and rebound viruses emerging during treatment interruption
    Lu, Ching-Lan, Pai, Joy A., Nogueira, Lilian, Mendoza, Pilar, Gruell, Henning, Oliveira, Thiago Y., Barton, John, Lorenzi, Julio C. C., Cohen, Yehuda Z., Cohn, Lillian B. et al. · 2018 · Proceedings of the National Academy of Sciences
  100. Two sides of a cellular coin: CD4(+)CD3- cells regulate memory responses and lymph-node organization
    Lane, Peter J. L., Gaspal, Fabrina M. C., Kim, Mi-Yeon · 2005 · Nature Reviews Immunology